KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Current Assets: 2009-2025

Historic Current Assets for Biomarin Pharmaceutical (BMRN) over the last 17 years, with Sep 2025 value amounting to $3.9 billion.

  • Biomarin Pharmaceutical's Current Assets rose 26.11% to $3.9 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $3.9 billion, marking a year-over-year increase of 26.11%. This contributed to the annual value of $3.2 billion for FY2024, which is 9.35% up from last year.
  • Latest data reveals that Biomarin Pharmaceutical reported Current Assets of $3.9 billion as of Q3 2025, which was up 1.29% from $3.8 billion recorded in Q2 2025.
  • Over the past 5 years, Biomarin Pharmaceutical's Current Assets peaked at $3.9 billion during Q3 2025, and registered a low of $2.3 billion during Q4 2021.
  • Over the past 3 years, Biomarin Pharmaceutical's median Current Assets value was $3.1 billion (recorded in 2024), while the average stood at $3.2 billion.
  • Its Current Assets has fluctuated over the past 5 years, first fell by 15.60% in 2021, then rose by 26.11% in 2025.
  • Quarterly analysis of 5 years shows Biomarin Pharmaceutical's Current Assets stood at $2.3 billion in 2021, then grew by 20.98% to $2.8 billion in 2022, then climbed by 7.44% to $3.0 billion in 2023, then increased by 9.35% to $3.2 billion in 2024, then climbed by 26.11% to $3.9 billion in 2025.
  • Its Current Assets was $3.9 billion in Q3 2025, compared to $3.8 billion in Q2 2025 and $3.5 billion in Q1 2025.